NanOlogy Launches Drug Development Program Targeting Rare Pediatric Brainstem Tumor
NanOlogy, LLC announced a new drug development initiative focused on treating diffuse intrinsic pontine glioma (DIPG), a highly aggressive and lethal pediatric brainstem tumor with few effective treatment options. The company is developing a formulaton of cisplatin using its Large Surface Area Microparticle (LSAM) technology for direct stereotactic intratumoral delivery to improve drug targeting and reduce systemic toxicity. NanOlogy is completing FDA-required investigational new drug (IND) enabling studies and plans to submit an IND application, with hopes of starting a clinical trial in late 2026, pending regulatory approval. Compared to traditional systemic cisplatin, this local delivery approach aims to bypass the blood-brain barrier and provide continuous drug exposure at the tumor site. 
NanOlogy Launches Drug Development Program Targeting Rare Pediatric Brainstem Tumor